CD4 and colonic neoplasm: According to the current research, administering LME to colon cancer-model rats significantly reduced their levels of AFP, CEA, and CA 19.9, as well as immune-inflammatory markers (TNF-α and IL-1β) matched with the development of apoptotic biomarker (CD4+), compared to the control group.